Archive for the ‘nih grantwriter’ Tag

New Webinar: NIH Submission Strategies — Register Now!

You have a cool idea for a research project, now what? The second in my new webinar series addresses NIH Submission Strategies. As a person who works on NIH submissions full time, I know there are certain steps you can take before you write a single word that correlate with better scores and outcomes.

Some of these steps include the following: taking the time to understand the priorities of the stakeholders involved, including reading Appropriations Reports; learning which projects are already in the NIH funding portfolio to ascertain how you might adjust your idea to fit in; identifying multiple ICs (not just an obvious one) and shopping around different versions of your Specific Aims to gauge enthusiasm; building a relationship with the all-important Program Officer, who will help guide questions related to study design, FOA, ESI status, and study section; and understanding the review process and audience before you write.

Your team will invest hundreds of hours in your submission. Why not spend 90 minutes learning some tried-and-true strategies to use before you write that will optimize your chance of success? I probably work on more NIH submissions in a month than you will work on across your entire career. I’ve helped clients land over $200 million in federal funds, and I can help strengthen your submission and improve your grantsmanship as well.

Bundle with two more webinars and save! Three webinars for $499.

Read about all three webinars, including “Mistakes Commonly Made on NIH Grant Applications” and “How To Write The Specific Aims.”

NIH Submission Strategies

Who: Essential for grantees planning to submit an R01, R21, or R03 in an upcoming cycle, and the senior faculty and administrators who advise them.
When: Wednesday 11 February 2015, 11am-12:30pm EST or
Thursday 19 February 2015, 11am-12:30pm EST
Cost: $199; Or register for all three webinars this month for $499
Takeaways: At the end of this 90-minute session, participants will be able to:

1. Utilize the Reporter website to identify their niche in the funding portfolio
2. Identify likely ICs, POs, and FOAs
3. Write several drafts of their Aims to send to POs
4. Choose the most appropriate IC, FOA, and study section with PO guidance


Posted February 5, 2015 by Meg Bouvier in Freelance medical writing, medical grant writing, NIH grantwriting

Tagged with , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

NIH Simplifies Policy on Late Applications

NIH might give you a two-week grace period on late applications. For details, see the Notice issued Dec 2014.

Examples of Reasons Why Late Applications Might Be Accepted

  • Death of an immediate family member of the PD/PI (or MPI).
  • Sudden acute severe illness of the PD/PI (MPI) or immediate family member.
  • Temporary or ad hoc service by a PD/PI on an NIH advisory group during the two months preceding or the two months following the application due date. Examples of qualifying service include: participation in an NIH study section/special emphasis panel, NIH Board of Scientific Counselors, Program Advisory Committee, or an NIH Advisory Board/Council. Qualifying service does not include participation in NIH activities other than those involved in extramural/intramural peer review or NIH Advisory Council/Board service.
  • Delays due to weather, natural disasters, or other emergency situations, not to exceed the time the applicant organization is closed.
  • For PD/PIs who are eligible for continuous submission (, the late application policy applies to activities not covered under the continuous submission policy (i.e., other than R01, R21, and R34 funding opportunities that use standard due dates).


Examples of Reasons Why Late Applications Will Not Be Accepted

  • Heavy teaching or administrative responsibilities, relocation of a laboratory, ongoing or non-severe health problems, personal events, participation in review activities for other Federal agencies or private organizations, attendance at scientific meetings, or a very busy schedule.
  • Review service for participants other than a PD/PI or MPI, acute health issues or death in the family of a participant other than a PD/PI or MPI.
  • Problems with computer systems at the applicant organization, problems with a system-to-system grant submission service, or failure to complete or renew required registrations in advance of the application due date.
  • Failure to follow instructions in the Application Guide or funding opportunity announcement.
  • Correction of errors or addressing warnings after 5 PM local (applicant organization) time on the application due date. Applicants are encouraged to submit in advance of the due date to allow time to correct errors and/or address warnings identified in the NIH validation process.

– See more at:

NIH Grantwriting Webinar Series Begins in February 2015!

We are happy to announce that in addition to one-on-one consulting, workshops, and seminars, we are now adding webinars to our menu of options to help NIH grantees. Upcoming webinars:

Mistakes Commonly Made On NIH Grant Applications
Benefit from the knowledge gained by a grantwriter who reads dozens of Summary Statements per year.

Wednesday 4 February, 11am-12:30pm EST or Thursday 12 February, 11am-12:30pm EST

NIH Submission Strategies
Take steps to optimize your chance of success before you write.

Wednesday 11 February, 11am-12:30pm EST or Thursday 19 February, 11am-12:30pm EST

How To Write The Specific Aims Of An NIH R01
Learn how to make the most important section of your submission compelling and persuasive.

Wednesday 25 February, 11am-12:30pm EST or Tuesday 3 March, 11am-12:30pm EST

Learn More!

NIH Issues Draft Policy That Would Require A Single IRB For Multi-Site Clinical Trials

For years, grantees have been encouraged to use a shared IRB in multi-site clinical trials as part of shared research networks at NCI, and it appears to increase efficiency without compromising protection. In early December 2014, NIH released a draft policy proposing that multi-site trials in the U.S. be required to use a single IRB. NCI has already conducted an analysis demonstrating that a single IRB decreases time and costs when compared to having individual IRB at each participating clinical site. To read and comment on the draft policy, click here. NIH is eliciting input until January 29, 2015. A commonly used model of joint IRB review is IRBshare, which according to its website “facilitates the sharing of full board approved documents between IRBs, accelerates the initial review process by enabling a temporary reliance between IRBs, and minimizes the need for all sites to conduct a full board review.” See the IRBshare website for details.

Ketamine — A New Drug Treatment For Depression?


Credit: Koratmember at

Remember ketamine, the old veterinary (and sometimes street) drug? Apparently it rapidly and significantly reduces anhedonia in those with treatment-resistant bipolar disorder, according to a new study.

Anhedonia, which is a lack of interest in activities that once gave a person pleasure, is a key feature of treatment-resistant bipolar disorder. According to a recent NIH-funded clinical trial, ketamine restored pleasure-seeking behavior independent of its other antidepressant properties in these patients. What’s more, it did so about 40 minutes after a single infusion, and the effect lasted as long as 14 days.

To me the most interesting part of this study is that ketamine did not act on the midbrain areas typically involved in depressive symptoms. Rather, PET scans on patients in the depressive phase of bipolar disorder showed that after ketamine infusion, there was activity in the dorsal anterior cingulate cortex (dACC). This region lies deep within the brain, resting on the medial surface of the frontal lobes. Its precise role remains somewhat elusive, though it is thought to govern conscious control of goal-directed behavior. The most recent significant study I could find on its function was a 2012 paper in Nature suggesting that the dACC is involved in optimizing behavioral adaptations to continuously evolving demands by predicting the difficulty of a task.

“Our findings help to deconstruct what has traditionally been lumped together as depression,” explained Carlos Zarate, M.D., of NIMH. “We break out a component that responds uniquely to a treatment that works through different brain systems than conventional antidepressants — and link that response to different circuitry than other depression symptoms.”

Imaging studies similar to the one just published are underway in patients with major depression, though results are not yet available. Other studies have suggested that ketamine may be exerting these effects through glutamate and dopamine pathways. Research is underway to explore easier methods of drug delivery, such as nasal spray.

Of late, ketamine has been studied for its rapid antidepressant properties, providing relief within hours rather than the weeks required for traditional medications to work. At present, ketamine is not FDA approved for treatment of depression and it is still used primarily in a veterinary setting.

Ketamine is an NMDA receptor antagonist, though it also inhibits reuptake of dopamine, serotonin, and norepinephrine. It was developed in 1962 and has been used in both humans and animals. It is categorized as a dissociative agent. It has been used for general anesthesia, sedation, and as a pain killer. Side effects include amnesia and agitation, and its street use has led to hallucinations, delirium, and death.

NIH Awards $31M To Increase Diversity in The Biomedical Research Workforce

Credit: Photokanok at

Credit: Photokanok at

In late October, NIH issued a news release stating that it will award $31 million to enhance diversity in the biomedical research workforce in FY14. The award will go to over 50 recipients who will be part of the national Diversity Program Consortium, established to engage researchers from underrepresented backgrounds. Award recipients work at geographically diverse institutions across the country that serve underrepresented communities. Members of the consortium will develop, implement, and evaluate methods for encouraging individuals to pursue careers in biomedical research and remain in this field.

Research shows that economic, social, and cultural factors significantly influence the pursuit of science careers. Dr. Hannah Valentine, NIH chief officer for scientific workforce diversity, asserts, “These awards represent a significant step toward ensuring that NIH’s future biomedical research workforce will reflect the unique perspectives found within the diverse composition of our society.”

The Diversity Program Consortium is part of a five-year plan with three major initiatives. The goal of the first initiative, BUILD, is to explore new approaches to attract students from diverse backgrounds to the biomedical science workforce. The goal of the second initiative, the National Research Mentoring Network (NRMN), is to develop best practices for mentoring individuals from underrepresented groups. Finally, work carried out as part of the Coordination and Evaluation Center is designed to assess the effectiveness of the training and mentoring approaches developed by BUILD and NRMN. It will also establish short- and long-term methods for measuring the effectiveness of both training and mentoring programs.

Scientists Explore Shared Biology In Human, Fly, and Worm Genomes



Credit: rajcreationzs at

Researchers analyzing human, fly, and worm genomes have found that these species have a number of key genomic processes in common, reflecting a shared ancestry. Three papers were published in the Aug. 28, 2014 issue of Nature offering insights into embryonic development, gene regulation, and other biological processes vital to understanding human biology and disease.

These studies utilized data generated by the model organism ENCyclopedia Of DNA Elements (modENCODE) and the ENCyclopedia Of DNA Elements (ENCODE) Project, both supported by NHGRI. Launched in 2007, the goal of modENCODE is to create a comprehensive catalog of functional elements in the fruit fly and roundworm genomes for use by the research community. Initial catalogs were published in 2010. The ENCODE Project is building a comprehensive catalog of functional elements in the human and mouse genome.

More than a dozen modENCODE Consortium papers have been or will be published in the journals Nature, Genome Research, Genome Biology, and the Proceedings of the National Academy of Sciences this year. This collection of papers is the culmination of the modENCODE program, for which funding ended in 2012. More than 100 papers using modENCODE data by groups outside of the program have already been published. It is anticipated that the data and resources produced by modENCODE will continue to be used by the broader research community for years to come.

Top Ten Things NIH Reviewers Should NOT Say In A Review


Credit: Ambro at

The Center for Scientific Review publishes their Peer Review Notes three times a year, and the most recent issue came out yesterday. The news items are always interesting and it is worth subscribing, if you don’t already. This issue contained an item about things NIH reviewers should not say. I repeat the list in its entirety here—I thought it might be fun for my grantees to see reviewers critiqued for a change.

What do you think of this list? Have you seen one or two of these on your Summary Statements? Me personally? I have seen variations on # 2, 4, and 10 in Summary Statements, and have strongly suspected reviewers of #1 and 5. I almost fell out of my chair laughing when I read # 7, sometimes I think CSR is a little out of touch with what actually happens on Study Sections:

  1. “I didn’t read the application, but I scanned it and saw the applicant said XXX. He doesn’t know what he’s doing.” Damning statements like this can skew a review discussion over something that might be insignificant in the context of the overall application. It’s better for you to ask other reviewers who have read the application carefully what they think about XXX.
  2. “This New Investigator does not appear to be fully independent since he continues to co-publish with his fellowship mentor/department chair, or does not have designated lab space, or has not been promoted in the past several years.”  Academic research organizations have widely diverse policies for faculty advancements and lab space, and many PIs maintain productive and healthy collaborations with mentors for many years after establishing themselves as bona fide investigators. You should focus more on the investigator accomplishments, such as being the first or senior author on a significant publication or giving presentations at major scientific meetings.
  3. “This application is not in my area of expertise . . . “  If you’re assigned an application you feel uncomfortable reviewing, you should tell your Scientific Review Officer as soon as possible before the meeting.
  4. “I don’t see this basic science research affecting my clinical practice any time soon.” An application does not necessarily have to show the potential for clinical or timely impact—if the applicant doesn’t make such claims. Basic research often takes time to pay off, and you’re charged to assess the “likelihood for the project to exert a sustained, powerful influence on the research field(s) involved.” Absence of an effect on public health does not necessarily constitute a weakness in basic science.
  5. “I like this project but I’m giving it a poorer score because the applicant has too much money.” Other funding is not a scoreable matter. You should focus on the application’s scientific and technical merit. However, you can note an excessive budget request in the budget section for NIH to consider.
  6. “This application has 2 great aims and 1 bad one. I would recommend deleting Aim 3, and I can give it a 1 or 2.” You cannot trade aims with scores. The application needs to be evaluated as a whole.
  7. “This R21 application does not have pilot data, which should be provided to ensure the success of the project.” R21s are exploratory projects to collect pilot data. Preliminary data are not required, although they can be evaluated if provided.
  8. “The human subject protection section does not spell out the specifics, but they already got the IRB approval, and therefore, it is ok.” IRB approval is not required at this stage, and it should not be considered to replace evaluation of the protection plans.
  9. “This application was scored a 25 and 14th percentile last time it was reviewed . . . .” You should not mention the previous score an application got, because this could skew the review discussion. Focus on the strengths and weaknesses of the current application as well as the responses to previous critiques.
  10. “This is a fishing expedition.” It would be better if you said the research plan is exploratory in nature, which may be a great thing to do if there are compelling reasons to explore a specific area. Well-designed exploratory or discovery research can provide a wealth of knowledge.

NIH Funding to Study Sex as a Fundamental Variable in Clinical Research

Credit: Photokanok at

Credit: Photokanok at

I am popping up from my mountain of R01 drafts to bring attention to an important NIH news release. Yesterday, NIH announced it has devoted over $10 million in supplemental funding for 82 grantees to explore sex differences in their clinical and pre-clinical research.

The news release states, “These awards are the latest round of funding in a program described in a May 2014 Nature commentary by [Janine Austin Clayton, M.D., NIH associate director for women’s health research] and NIH Director Francis S. Collins, M.D., Ph.D. This commentary informed NIH grantees and other stakeholders of the agency’s intent to develop policies that will require applicants to address the influence of sex in the design and analysis of biomedical research with animals and cells.”

The news release states that the goal of the supplements is to serve as “…a catalyst for considering sex as a fundamental variable in research.”

NIH began this program in FY13, initially funding 50 supplements ($4.6 million total.) The initiative has been led by the Office of Research on Women’s Health. Most of the NIH ICs have funded supplements since the inception of the program.

Historically, medical research has been conducted predominantly on white male subjects. NIH has made efforts to expand the scope of clinical research to include both sexes and to represent multiple races and ethnicities. Grantees who want to succeed in the NIH arena would be wise to incorporate such variables into current and future studies.



Rapid Advances in Ebola Research

The current Ebola outbreak is by far the largest since this hemorrhagic fever was identified in 1976. Previous outbreaks involved dozens or hundreds of infected people (click here for CDC chronology). Estimates of the current outbreak are 2,473 infections and 1350 deaths thus far. Outbreaks begin by transmission through close contact with infected animals, then rapidly spread through human communities via direct contact with bodily fluids of infected people, or through contact with items contaminated with such fluids. Once infected, case fatality is as high as 90% (click here for WHO fact sheet). There are currently no vaccines, treatments, or cures. Traditionally, outbreaks have been controlled largely by infection control measures (masks, gloves, etc.) and quarantine, and supportive care such as hydration of the infected patient.


Experimental Treatments: A promising drug called ZMAPP was given at Emory University to two missionaries who were infected with Ebola. Both have gotten better. The drug was also given to a Spanish priest who died soon thereafter, though the timing of drug delivery may have played a part in the drug’s efficacy in this case. As of this week, it appears to be helping three Liberian health care workers. The drug is manufactured by Mapp Biopharmaceutical Inc. It is not FDA approved at present, nor can this monoclonal antibody be produced quickly in large quantities. Other drugs are in development but have yet to show as much promise as ZMAPP. Ebola is a rare disease and affects poor countries almost exclusively, so limited funding is provided mostly by government agencies (see $28 million consortium led by Scripps and funded by NIH, and the recent $10.8 million initiative announced by Wellcome Trust and the United Kingdom’s Department of International Development.) I generally distrust .com coverage of anything related to medicine (and so should you), but this recent CNN piece on ZMAPP seems reasonable, if you would like more information.


Cause of the Current Outbreak: NIH announced this morning that researchers funded by NIH have used advanced genomic analysis to determine the single point of infection from an animal that led to the current outbreak, and that since that initial infection the spread has been solely human to human. Importantly, through their genetic analysis, the researchers can see how the virus has mutated since December to outsmart human immune systems. As we know, viruses are little more than tiny pieces of DNA that can mutate with diabolical speed to outsmart the comparatively slow human immune response. By understanding how infection occurs, how disease is spread, and how viruses are mutating to defy immune attack, these researchers have taken a giant step toward improved treatments and a cure. The team was led by Pardis Sabeti, MD, PhD (who not surprisingly won a highly prestigious NIH Director’s New Innovator award in 2009.)


Experimental Vaccines: Next week, NIAID will begin the first of several phase I clinical trials of an Ebola vaccine produced in collaboration with GlaxoSmithKline (for details, click here). They will also test an Ebola vaccine developed by the Public Health Agency of Canada and licensed to NewLink Genetics Corp. NIH will partner with a British-based international consortium to test volunteers in the UK, and in the West African countries of Gambia (with approval of local authorities) and Mali. The CDC is in discussion with Nigerian officials about testing vaccines there.

%d bloggers like this: